Results 271 to 280 of about 75,748 (340)

Global Resource Disparities Between Pulmonary Hypertension Centers: Results From the International Survey by the PVRI IDDI Access to Care Workstream

open access: yesPulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT There is a limited understanding of how pulmonary hypertension (PH) patients are managed worldwide. The Pulmonary Vascular Research Institute (PVRI) Innovative Drug Discovery Initiative (IDDI) global survey attempted to obtain insights into access to PH care in diverse international regions to pave future action plans.
Sasha Z. Prisco   +9 more
wiley   +1 more source

Sotatercept in Pulmonary Langerhans Cell Histiocytosis‐Associated Pulmonary Hypertension: A Case Series and Systematic Review

open access: yesPulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Pulmonary Langerhans cell histiocytosis (PLCH) frequently complicated by pulmonary hypertension (PH), which markedly worsens prognosis. We retrospectively reviewed three institutional PLCH‐PH cases treated with off‐label Sotatercept added to background triple therapy and performed a systematic review of published PLCH‐PH reports (PubMed/Embase
Giorgi Chilingarashvili   +7 more
wiley   +1 more source

NT-proBNP to guide risk stratification after cardiac rehabilitation in patients with ST-segment elevation myocardial infarction

open access: hybrid
Nerea Pérez-Solé   +15 more
openalex   +1 more source

Subcutaneous Treprostinil in PH Associated With Left Heart Disease or Chronic Lung Disease

open access: yesPulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Pulmonary hypertension (PH) associated with left heart disease (LHD‐PH) and pulmonary hypertension associated with chronic lung disease (CLD‐PH) are the most common PH subtypes but lack effective treatments. In a prospective cohort study, 90 patients (39 LHD‐PH, 51 CLD‐PH) with severe disease [pulmonary vascular resistance (PVR) > 5 Wood units
Roela Sadushi‐Koliçi   +8 more
wiley   +1 more source

Methamphetamine‐Associated Pulmonary Arterial Hypertension: Impact, Mechanisms, and a Framework for Management

open access: yesPulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Methamphetamine‐associated pulmonary arterial hypertension (Meth‐PAH) is an increasingly prevalent but understudied subtype of Group 1 pulmonary arterial hypertension (PAH). While most prevalent in the Western United States, its reach continues to expand with the evolving global methamphetamine epidemic.
Namita Sood   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy